BioMarin Pharmaceutical (BMRN) Financial Analysis & Valuation | Quarter Chart
BioMarin Pharmaceutical (BMRN)
BMRNPrice: $62.62
Fair Value: 🔒
🔒score
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage... more
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-... more
Description
Shares
| Market Cap | $12.03B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Alexander Hardy |
| IPO Date | 1999-07-26 | CAGR | 0.34% |
| Employees | 3,040 | Website | www.biomarin.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | 0.64% | Total Yield | 0.64% |
BMRN chart loading...
Fundamentals
Technicals
| Enterprise Value | $10.70B | P/E Ratio | 22.33 |
| Forward P/E | 8.1 | PEG Ratio | — |
| P/S Ratio | 3.89 | P/B Ratio | 1.98 |
| P/CF Ratio | 14.52 | P/FCF Ratio | 16.59 |
| EPS | $2.69 | EPS Growth 1Y | 59.28% |
| EPS Growth 3Y | 542.2% | EPS Growth 5Y | -39.13% |
| Revenue Growth 1Y | 12.39% | Gross Margin | 0.81% |
| Operating Margin | 0.2% | Profit Margin | 0.17% |
| ROE | 0.09% | ROA | 0.07% |
| ROCE | 0.09% | Current Ratio | 5.21 |
| Quick Ratio | 3.5 | Cash Ratio | 1.73 |
| Debt/Equity | 0.1 | Interest Coverage | 57.53 |
| Altman Z Score | 6.11 | Piotroski Score | 5 |